Patients must be accessible for treatment and follow-up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.
Amenable to follow up examinations
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
Patients whose circumstances do not permit completion of the study or the required follow-up
Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
Patients who have circumstances that will not permit completion of this study or the required follow-up
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up.
Patients with circumstances that will not permit completion of the study or the required follow-up
Patients must have a body surface area >= 0.37 m^2 at enrollment while the 120 mg strength tablet supply is available; patients < 0.73 m^2 must follow the dosing nomogram; patients >= 0.73 m^2 at enrollment must follow the dosing nomogram
Be willing to return to the center for all study-related follow up procedures, including blood collections and completion of imaging studies as required by the protocol
Participants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issue
Subject has voluntarily agreed to abide by all protocol required procedures including study related assessments, and management by the treating institution for the duration of the study and long-term follow-up.
Active psychosocial condition that would hinder study compliance and follow-up
Lack of availability for immunological and clinical follow-up assessment.
Patients whose circumstances do not permit completion of the study or the required follow-up
Psychiatric condition making the patient unlikely to comply with protocol therapy, required tests and follow-up.
Reliable and willing to make themselves available for the duration of the study and are willing to follow study-specific procedures.
Patients must have the psychological ability and general health that permits informed consent, completion of the study requirements, and required follow up
Patients must be accessible for treatment and follow up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
Patient must be accessible for treatment and follow-up.
Patient with inability to follow up.
Patients who have the ability to collaborate planned follow-up
Lack of availability of a patient for immunological and clinical follow-up assessment
Available for follow up
Patients must be willing to receive follow-up care for a minimum of five years after treatment at the treating institution, including annual follow up visits; in the event that the patient is not from the local area and returning to the treating institution for follow up visits is too difficult, they must be willing to have their outside medical information (i.e. imaging studies, laboratory results and doctor or other health professional notes) released to the treating institution to track the results of treatment
TREATMENT WITH SJCAR19: Agreement to participate in long-term follow-up on protocol NCT00695279
Patients must agree to participate in long-term follow-up for up to 15 years if they are enrolled in the study and receive T cell infusion
Inability to follow standard of care follow up recommendations per investigator discretion
Patient agrees to have 10 week follow-up visit at a participating Johns Hopkins facility
Patient agrees to allow access to or provide clinical, imaging, and laboratory follow-up information for until time of death or data analysis, whether or not obtained from Johns Hopkins providers
Any underlying condition which prevents the patient from being able to undergo the required number of sessions of PDT or RT and required follow up
Amenable to regular follow-up (according to research policies) for at least 5 years
Must be willing to participate in Gene Therapy Long Term Followup Protocol (15-C-0141), which will follow patients for up to 15 years per Food and Drug Administration (FDA) requirements
Ability to cooperate with study treatment and follow-up.
Signed consent to long-term follow-up protocol PA17-0483.
Lack of availability of a patient for immunological and clinical follow up assessment
Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Presence of psychiatric or neurologic disease, or lack of social support that limits patient's ability to comply with the treatment protocol including supportive care, follow-up, and research tests
Patients who have circumstances that will not permit completion of this study or the required follow-up
Lack of availability of a patient for immunological and clinical follow-up assessment
Agree to follow protocol required evaluations
Patients must be able to return to surgical facility for 30 and/or 90 day (+/- 20 days) follow up appointment
Willing and able to comply with the protocol, scheduled follow-up, and management of toxicity as judged by the Investigator. Cohort 3B (Combination Expansion): Osteosarcoma subjects who progressed in Cohorts 1 or 2B and opt to receive combination therapy.
Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.
Physician plans to remove the stent within the duration of study follow-up
Patients whose circumstances do not permit completion of the study or the required follow-up
Patients must be willing to receive follow-up care for a minimum of 5 years after treatment at participating institution(s) and annual visits unless it is too difficult to return to participating institution for follow-up care; in that event, patients must be willing to have outside medical information released in order to track the results of treatment
All pre-study and follow-up imaging studies preferably performed at City of Hope
Patient must be willing to return to the treating physician’s office for outpatient follow-up once outpatient treatment is completed
Physical or emotional status that would prevent informed consent, protocol compliance, or adequate follow-up
Patients must demonstrate the ability and willingness to follow the study requirements.
Patient compliance and geographic proximity (as determined by the Principal Investigator) that allow adequate follow-up.
Females - not pregnant and willing to follow contraceptive guidance
Males - Willing to follow contraceptive guidance
Must be accessible for treatment and follow up. Patients registered on this trial must be treated with chemotherapy and followed at the enrolling centre.
Patients able to complete study and within geographical proximity allowing for adequate follow up
Must be available during the duration of the study and willing to follow the study procedures
Patients whose circumstances do not permit completion of the study or the required follow-up
Inclusion Criteria:\n\n        Subjects who meet the following criteria will be eligible to participate in the Long-Term\n        Follow-Up study:\n\n          1. All adult and pediatric subjects who received at least one GM T cells infusion in a\n             previous Celgene sponsored or Celgene alliance partner sponsored study, and have\n             discontinued, or completed the post-treatment follow-up period in the parent treatment\n             protocol, as applicable.\n\n          2. Subject (and, parental/legal representative, when applicable) must understand and\n             voluntarily sign an Informed Consent Form/Informed Assent Form prior to any\n             study-related assessments/procedures being conducted.\n\n          3. Subject is willing and able to adhere to the study visit schedule and other protocol\n             requirements.\n\n        Exclusion Criteria:
Failure to demonstrate adequate compliance with medical therapy and follow-up
Signed consent to long-term follow- up protocol PA17- 0483
Patient must be available for follow-up
Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
Lack of ability of a patient for immunological and clinical follow-up assessment
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow-up
Participants must be able and willing to follow protocol instructions and schedules
Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care
Subjects willing for repeat oral dosing and follow-up, including pharmacokinetic\n             sampling
Not willing to follow protocol requirements or to give informed consent
Available for long-term follow-up of their disease after treatment
Emotional limitations, which the investigator judges could limit the patient's ability to follow up and comply with study procedures
Patients whose circumstances do not permit completion of the study or the required follow-up
Patients who have circumstances that will not permit completion of this study or the required follow-up
Patients must have the ability and willingness to come to Clinical Center for bi-weekly follow-up appointments
Accessible for follow up
All male and female subjects must follow all requirements defined in the Pregnancy Prevention Program.
Agrees to follow protocol-defined method(s) of contraception
Must agree to follow pregnancy precautions as required by protocol.
Patients whose circumstances at the time of study entry do not permit completion of the study or required follow-up
Agree to follow a low lycopene and phytoene diet
Patients must be willing to receive follow-up care for a minimum of five years after treatment at Massachusetts General Hospital (MGH) and annual visits unless it is too difficult to return to MGH for follow-up care; in that event, the patient or guardian must be willing to have their outside medical information (i.e. imaging studies, laboratory results and doctor or other health professional notes) released in order to track the results of treatment
Be in the survival follow-up phase of a previous duvelisib study
Have completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the Sponsor
Lack of availability for immunological and clinical follow-up assessment.
Available for the duration of the study and are willing to follow study-specific procedures.
Willingness to return to University of Maryland Greenebaum Cancer Center (UMGCC) or other participating institutions for treatment and follow-up
Study team (PI, co-investigator [I], and/or research nurse) may deny enrollment if in the study team’s opinion, the candidate may not be adherent to the treatment protocol including scheduled follow-ups
Is able and willing to follow all study procedures
Is unable to follow study procedures
Able to comply with scheduled follow-up and with management of toxicity
Lack of availability of a patient for immunological and clinical follow-up assessment
Able to comply with scheduled follow-up and with management of toxicity.
Patients who have circumstances that will not permit completion of this study or the required follow-up
Patients for whom completion of this study and/or follow-up is deemed inappropriate for any reason
Willing to follow pregnancy precautions
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Ability to read and follow instructions
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Patient must be available for follow-up; after 2 years of follow-up following post-treatment biopsy, telephone-based follow-up will be acceptable
The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol.
Must agree to follow pregnancy precautions as required by the protocol.
Patient compliance and geographic proximity that do not allow adequate follow-up
Patients regardless of eligibility to liver transplant, who have a comorbid disease that might preclude completion of study follow-up.
Accessible for treatment and follow-up
Patient compliance and geographic proximity that allow adequate follow-up
Willingness to follow pregnancy precautions.
Patients must be accessible for treatment and follow up.
PART II: The oncology participants must have study approved by oncologist responsible for management of care or follow up
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Patients who in the opinion of the Investigator would not be able to provide reliable study data or be available for study follow-up
Patients must be accessible for treatment and follow-up; investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
Participants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issue
Mentally, physically, and geographically able to undergo treatment and follow up
Reliable and available for the duration of the study and willing to follow study procedures.
Lack of availability of a patient for immunological and clinical follow-up assessment
Refusal to participate in the long-term follow-up protocol (2006-0676)
Patient must be accessible for follow-up
Subject has agreed to abide by all protocol required procedures including study related assessments, and management by the treating institution for the duration of the study and long term follow-up.
Subject agrees to comply with follow-up procedures, including returning for all follow-up visits
Cancer treatment or follow-up for lymphoma at the Massachusetts General Hospital (MGH) Cancer Center
Patients who are able to follow-up in person during the trial
Women must be willing to receive follow up care either at Hopkins or with their local oncologist for at least 1 year
Patients not available for follow-up testing
PHASE 1: PATIENT ELIGIBILITY: At least 1.5 years from treatment (which is a typical time for preparation to transfer to long-term follow-up care)
Unwilling to undergo routine follow-up
Able and willing to follow prescribed diet intervention
Patients who are local and able to follow-up in the SCC within 30 days if necessary
Able to follow instructions
Patients who are unable to follow instructions due to their medical condition
Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
Patients not available for follow-up tests
Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
Long-term follow up must be possible
Willing to undergo a form of cancer therapy and subsequent follow-up care
Followed in the Adult Long Term Follow Up Program
Not willing or able to follow procedures specified by the study and/or instructions of the researcher; prior to randomization, participants must provide a signed authorization and medical clearance from their personal physician or our nurse practitioner
Patients enrolled on phase 1 of the study are eligible (and/or if recruited from tumor registry or clinic follow-up schedules)
Patient must still be in active follow-up: seen for a follow-up visit in the participating center at least once in the 3 years prior to enrollment and/or scheduled to be seen for follow-up in the next 6 months (i.e. in active follow-up)
Unavailability for follow-up
Subject will not be available for follow-up assessment
Inability to commit to local follow up for device management
Those unwilling to participate in the follow-up call 3 months post-surgery
Willing to provide locator information for follow-up contact
The subject agrees to follow-up examinations out to 6 months post-treatment
Available for follow-up over the course of the study;
Not available for follow-up over the course of the study;
The subject is willing to comply with 30-day follow-up in the office and answer quality-of-life questionnaires per protocol
The subject is willing to comply with 90-day follow-up by phone
The subject is not willing to comply with 60-day follow-up in the office and answer quality-of-life questionnaires per protocol
The subject is not willing to comply with 90-day follow-up by phone
Willing to follow protocol requirements
Patients who previously participated in this study and are returning to the Women’s Imaging Center for follow-up diagnostic tests
Clinician is comfortable that cancer has adequately been ruled out and is willing to follow the participant for up to 5 years without treatment of the HSIL
Participants may have a history of indeterminate pulmonary nodule(s) by chest imaging if nodule follow-up has been completed or the study procedures would not interfere with nodule follow-up
Provide signed informed consent and agree to comply with all protocol-specified procedures (e.g., providing saliva samples; participating in five one-hour group sessions over a period of 22 days) and follow-up evaluations
RECIPIENT: Participant must be willing to comply with study and/or follow?up procedures, including willingness to be followed for one year post?HCT
Willingness to commit to follow-up with his/her primary care provider after completion of the Getting Ahead training program
Agree to follow a berry-free/controlled polyphenol diet and to document consumption of polyphenolic foods each day of the study using a simple daily form
Plans to move from Kansas City (KC) during the treatment and follow-up phase
Willing to take NRT for up to 12 months, and be willing to complete 4 follow-up telephone-based counseling sessions and 3 follow-up visits
FOLLOW-UP ASSESSMENTS: Be 50 years of age or older by the time of the 3-month telephone follow-up assessment
FOLLOW-UP ASSESSMENTS: Have telephone service (mobile or landline), to participate in the follow up interviews
Agree to participate in the study and be available for 6 weeks of treatment and 6 months of follow-up
Patients who are willing and capable to follow the instructions required to complete the study
Participants may have a history of indeterminate pulmonary nodule(s) by chest imaging if nodule follow-up has been completed or the study procedures would not interfere with nodule follow-up
Plans to move from Kansas Cancer Center (KC) during the treatment and follow-up phase
Patients with untreated focal liver observations scheduled for follow-up multiphase contrast-enhanced CT or MRI, biopsy or surgical excision as part of clinical standard of care; CEUS should be performed within 4 weeks before or after follow-up imaging or within 4 weeks before biopsy or surgical excision
Willing to come to MSK main campus for baseline and follow-up MP-MRIs
Patient can be reliably reached for post-MRI follow up adverse event (AE) check
Willing to sign release of information for any radiation and/or follow-up records
Agrees to allow access to clinical records regarding response to treatment and long term follow up
Willingness to comply with required follow up perometer and BIS measurements and completion of LEFT-BC questionnaire
Subject agrees to complete follow up visit
Patients must agree to allow access to clinical records regarding response to treatment and long term follow up
Patient must be available for follow-up
The patient agrees to follow-up examinations out to 5-years post-treatment
Patients must be willing to return to National Institutes of Health (NIH) for follow-up
Able and willing to follow study procedures and instructions.
Able and willing to follow study procedures and instructions.
Subjects must be able and willing to follow study procedures and instructions.
Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP)